AMSTERDAM--(BUSINESS WIRE)--Teva Pharmaceuticals Europe BV, (NYSE and TASE: TEVA) announced the winner of the tomy’s (Teva’s Orphan hematological Malignancies award for Young hematologists) at the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy last week. During the event entitled, ‘Next-Generation APL Leaders: Teva’s Award for Young Hematologists’ Dr. Salamero was awarded a tomy’s trophy, as well as a bursary to attend the 2017 American Society of Hematology (ASH) Annual Meeting, taking place in the USA in December.
Dr. Salamero is currently a hematologist at the Vall d’Hebron University Hospital, Barcelona, Spain and presented research entitled Very elderly acute promyelocytic leukemia: a multicentric experience. The study selected patients aged ≥ 75 years old with APL who had reported to PETHEMA registry (Spanish Hematology Treatment Programme) over the last nineteen years. Epidemiologic characteristics and disease features in the very elderly APL population were analysed and the percentage of patients treated according to investigators criteria described. The research found that patients treated with all-trans retinoic acid (ATRA) plus anthracycline-based regimen showed better outcomes than patients who received other strategies, such as ATRA alone, chemotherapy alone or best supportive care.
Speaking after the awards ceremony, Dr. Salamero said, “Winning the tomy’s - it’s been a pleasure. I feel proud, not because of my work but the work of the PETHEMA group. I would recommend attending the APL Symposium as not only is it very interesting, but it facilitates a lot and keeps you in touch with your peers.”
The tomy’s are an educational award programme for young hematologists, sponsored by Teva Oncology. The awards are open to young hematologists, or young physicians training to become hematologists aged 40 years or younger. The entrants are challenged to illustrate the latest scientific advancements in the management of orphan hematological malignancies by presenting a case study or case series demonstrating their excellence in education and presentation skills. The independent jury for the 2017 tomy’s was comprised of experts in orphan hematological malignancies and includes Pierre Fenaux, France; Richard Schlenk, Germany; Francesco Lo-Coco, Italy; Bob Löwenberg, Netherlands; Nigel Russell, UK and Miguel Sanz, Spain.
“It’s estimated that between 1,500 – 2,000 people in Europe are diagnosed with APL each year. Even though APL is the most lethal type of acute leukemia, it’s highly curable and more research into this disorder is urgently needed. The tomy’s programme reflects Teva’s commitment to encouraging new and innovative research aimed at improving patient outcomes in orphan hematological malignancies,” said Paul Harmon, Head of Teva’s Oncology Care and Transplant Europe.
“APL can cause a number of symptoms including uncontrollable bleeding and can kill within hours or days if left untreated. As it’s so rare, APL can be difficult to recognise and diagnose. We’re excited about this programme, and we believe it will stimulate new exciting research, with the ultimate ambition of saving lives,” commented Prof. Lo-Coco, tomy jury member.
The full list of finalists as well as more information on the jury can be accessed via: https://www.thinkapl.com/jury/
The tomy’s awards ceremony in Rome follows the inaugural tomy’s awards, announced at the Teva Oncology Satellite Symposium at the Acute Leukemias XVI International Symposium, which took place in Munich, Germany, in February 2017.
For more information on the Tomy’s awards or for queries regarding abstract submissions or notifications, please contact: support@oncotomys.com.
-ENDS-
About Teva
Teva is among the top 15 global pharmaceutical companies globally, delivering high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 60 markets every day. Teva produces a leading innovative treatment for multiple sclerosis and has late-stage development programs for a range of disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions. With its European headquarters in Amsterdam, the Netherlands, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a broad range of products in nearly every therapeutic area. Teva draws on its specialty and generics capabilities to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.
